Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Summary
This is a multicenter, single-arm, phase II clinical study to evaluate the safety and efficacy of Cadonilimab combined with gemcitabine, or vinorelbine, or pemetrexed in the treatment of patients with recurrent / refractory pleural mesothelioma.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
59
Start Date
2024-06-20
Completion Date
2029-06-20
Last Updated
2024-05-16
Healthy Volunteers
No
Conditions
Interventions
Cadonilimab Combined with chemotherapy
Cadonilimab (15mg/kg, intravenous drip, D1) + gemcitabine (1250mg/m2, intravenous drip, D1/D8) or vinorelbine (30mg, oral, tiw, D1/D3/D5) or pemetrexed (500mg/m2, intravenous drip, D1), every 3 weeks.